A characterisation study on the application of inverted lyotropic phases for subcutaneous drug release

An experimental characterisation of lipid mixtures consisting of inverted hexagonal and inverted cubic phases composed of soybean phosphatidylcholine (SPC) and glycerol dioleate (GDO) was performed. The release of five chromophores of varying lipophilicity, used as model drugs, was investigated. Two...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2010-03, Vol.388 (1), p.52-57
Main Authors: Rosenbaum, Erik, Tavelin, Staffan, Johansson, Lennart B.-Å.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Chemistry, Pharmaceutical - methods
Delayed-Action Preparations
Diglycerides - chemistry
Drug Carriers - chemistry
Drug Delivery Systems
Drug depot
General pharmacology
Glycine max - chemistry
Lipid formulations
Lipophilicity
Medical sciences
Model drugs
Pharmaceutical Preparations - administration & dosage
Pharmaceutical Preparations - chemistry
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Phosphatidylcholines - chemistry
Subcutaneous drug delivery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An experimental characterisation of lipid mixtures consisting of inverted hexagonal and inverted cubic phases composed of soybean phosphatidylcholine (SPC) and glycerol dioleate (GDO) was performed. The release of five chromophores of varying lipophilicity, used as model drugs, was investigated. Two experimental setups were applied: one based on maintaining sink condition, while a constant volume release medium was employed for the other. For neither setup, no correlation between the model drug lipophilicity and the polarity of the carrier matrix was found. However, the lipid phases showed a prolonged release, spanning weeks, of the model drugs, which exhibit lipophilicity values ranging by four orders of magnitude.
ISSN:0378-5173
1873-3476
1873-3476
DOI:10.1016/j.ijpharm.2009.12.032